Brief: NHS Says Awaiting Final Decision From NICE To Determine If Lecanemab Should Be Offered By NHS In England
22/08/2024 10:33
Aug 22 (Reuters) -
NHS:
* NHS-AWAITS FINAL DECISION FROM NICE FOR CLINICAL BENEFITS,
COST-EFFECTIVENESS OF LECANEMAB TO DETERMINE IF IT SHOULD BE
OFFERED BY NHS IN ENGLAND
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln